Bioactive Materials · 2022 · 58 citations · 32 references
PharmacyCardiologyPharmacologyBiomaterialsCardiovascular PharmacotherapyDrug DeliveryCardiovascular BiomaterialsEndothelial ActivationEndothelial DysfunctionNanomaterials For Drug DeliveryReactive Oxygen SpeciesReactive Oxygen Species-responsive Drug DeliveryAntithrombogenic BiomaterialsCoronary StentingDrug-eluting BiomaterialsIn-stent ThrombosisPlatelet-derived Growth Factor InhibitionReactive Oxygen Species GenerationStent BiomaterialsVascular Smooth Muscle Cell Proliferation
An increased level of reactive oxygen species (ROS) plays a major role in endothelial dysfunction and vascular smooth muscle cell (VSMC) proliferation during in-stent thrombosis and restenosis after coronary artery stenting. Herein, we report an electrospun core-shell nanofiber coloaded with 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPOL) and rapamycin (RAPA) that correspondingly serves as an ROS scavenger and VSMC inhibitor. This system has the potential to improve the biocompatibility of current drug-eluting stent (DES) coatings with the long-term and continuous release of TEMPOL and rapamycin. Moreover, the RAPA/TEMPOL-loaded membrane selectively inhibited the proliferation of VSMCs while sparing endothelial cells (ECs). This membrane demonstrated superior ROS-scavenging, anti-inflammatory and antithrombogenic effects in ECs. In addition, the membrane could maintain the contractile phenotype and mitigate platelet-derived growth factor BB (PDGF-BB)-induced proliferation of VSMCs. In vivo results further revealed that the RAPA/TEMPOL-loaded covered stents promoted rapid restoration of vascular endothelium compared with DES and persistently impeded inflammation and neointimal hyperplasia in porcine models.
32
Cardiovascular disease in Europe: epidemiological update 2016
Nick Townsend, Lauren Wilson, Prachi Bhatnagar et al. · European Heart Journal · 2016 · 1.6K citations · Full text
Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent
Renu Virmani, Giulio Guagliumi, Andrew Farb et al. · Circulation · 2004 · 1.5K citations · Full text
Medicine, Cardiology, Immunology +13
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
Eugène McFadden, Eugenio Stabile, Evelyn Regar et al. · The Lancet · 2004 · 1.4K citations
Medicine, Cardiology, Pharmacology +16
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease
Gregg W. Stone, Joseph F. Sabik, Patrick W. Serruys et al. · New England Journal of Medicine · 2016 · 1.1K citations · Full text
Medicine, Cardiology, Surgery +11